Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
) Drug Halves Attacks in Hard-to-Treat Asthma
8/17/2012 7:11:50 AM
An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success. Britain's biggest drugmaker - already a world leader in respiratory medicine - said as a result it planned to move the new drug into final Phase III development before the end of 2012. The injectable antibody treatment mepolizumab is designed to help a small group of people with asthma in which white blood cells called eosinophils cause inflammation of lung airways. It reduces the number of eosinophils by inhibiting an immune system signaling chemical called interleukin-5.
(GSK) India Unit to Shut Factory
(NVS) Eye Drug Shows Promise in Study
(GSK) Sells Australian Drugs to
Aspen Pharmacare Ltd.
for $270 Million
Novo Nordisk A/S
(NVO)’s Hemophilia Treatment "Blockbuster" Could be a Total Bust
Big Pharma Pilots,
Johnson & Johnson
(JNJ) Single-Page Drug Info Sheet
(AUXL) Reports Positive Top-line Data From XIAFLEX Phase IIIb Trial
(GSK)'s Olympic Doping Facility to Research Personalised Medicines After Games
Approves First Generic Copies of
Merck & Co., Inc.
(GSK) Mix Corporate Do-Gooding and Hard-Nosed Business?
Announces Scheduling of End-of-Phase 2 Meeting With
for MN-221 for the Treatment of Acute Exacerbations of Asthma
comments powered by Disqus.
comments powered by
Clinical - Phase III
Clinical - Phase III (World)